Abstract: Ｏｂｊｅｃｔｉｖｅ：To evaluate the efficacy of sacubitril／valsartan in peritoneal dialysis patients with heart failure.
Ｍｅｔｈｏｄｏｌｏｇｙ：102 peritoneal dialysis patients with heart failure treated with sacubitril／valsartan in the Department of Nephrology of the First Affiliated Hospital of Zhengzhou University were retrospectively analyzed. According to the left ventricular ejection fraction (LVEF), they were divided into HFrEF group (n=25), HFmrEF group (n=30) and HFpEF group (n=47). The cardiac indexes, laboratory indexes and adverse events of three groups were compared before and 6 months after the treatment.
Ｒｅｓｕｌｔｓ：After 6 months of treatment, LVEF, pulmonary artery systolic pressure (PASP), left ventricular enddiastolic diamerer (LVEDD), New York Heart Association (NYHA) classification, NTproBNP and hscTnI of three groups were significantly improved compared with that before treatment. The improvement degree of NYHA classification and NTproBNP in HFrEF group was better than that in HFmrEF group and HFpEF group, and the improvement degree of LVEF and hscTnI in HFrEF group and HFmrEF group was more obvious than that in HFpEF group (P<005). After 6 months of treatment, the level of hemoglobin in three groups increased significantly compared with that before treatment (P<005), and there was no significant difference in serum electrolyte, albumin or eGFR. There was no significant difference in the incidence of adverse events among three groups.
Ｃｏｎｃｌｕｓｉｏｎ：Sacubitril／valsartan can effectively improve the cardiac function in peritoneal dialysis patients with heart failure, with good safety. Among them, the therapeutic effect on HFrEF is the best and HFpEF is relatively worse.

Key words: sacubitril／valsartan,end-stage renal disease,peritoneal dialysis,heart failure,ejection fraction